title: Centrally applied nitric oxide donor elevates plasma corticosterone by activation of the hypothalamic noradrenergic neurons in rats.
abstract: The present study was undertaken to investigate the mechanisms involved in a nitric oxide donor [3-morpholino-sydnonimine (SIN-1)]-induced activation of hypothalamic-pituitary-adrenal axis in urethane- and alpha-chloralose-anesthetized rats. Intracerebroventricularly (i.c.v.) administered SIN-1 (250 and 500 microg/animal) effectively and dose-dependently elevated plasma levels of corticosterone. Pretreatment with phentolamine (250 microg/animal, i.c.v.), an alpha-adrenoceptor antagonist, attenuated the elevation of plasma corticosterone evoked by SIN-1, but sotalol (300 microg/animal, i.c.v.), a beta-adrenoceptor antagonist, was without effects. The same doses of SIN-1 also increased the release of noradrenaline in the hypothalamic paraventricular nucleus (PVN) measuring microdialysis technique, and this increase was abolished by tetrodotoxin (1 microM) administered into the perfusion solution of the PVN. Furthermore, pretreatment with indomethacin (500 microg/animal, i.c.v.), a cyclooxygenase inhibitor, abolished the SIN-1-induced elevations of both noradrenaline in the PVN and plasma corticosterone. These results suggest that i.c.v. administered SIN-1 activates central noradrenergic neurons innervating the PVN by prostaglandin-mediated mechanisms. Released noradrenaline in the PVN elevates plasma levels of corticosterone via an activation of the central alpha-adrenoreceptors in rats.
authors.affiliation: Department of Pharmacology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
authors.forename: Shoshiro
authors.initials: S
authors.lastname: Okada
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Murakami
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Yokotani
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D002698:Chloralose / Q000494:pharmacology; D003345:Corticosterone / Q000097:blood* / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007276:Injections, Intraventricular; D008297:Male; D017551:Microdialysis; D008981:Molsidomine / Q000031:analogs & derivatives / Q000494:pharmacology*; D009569:Nitric Oxide / Q000378:metabolism / Q000502:physiology*; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D009638:Norepinephrine / Q000378:metabolism*; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology*; D010646:Phentolamine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013015:Sotalol / Q000494:pharmacology; D013997:Time Factors; D014520:Urethane / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D016861:Cyclooxygenase Inhibitors; D020030:Nitric Oxide Donors; D002698:Chloralose; D009569:Nitric Oxide; D014520:Urethane; C002385:linsidomine; D013015:Sotalol; D008981:Molsidomine; D003345:Corticosterone; D009638:Norepinephrine; D007213:Indomethacin; D010646:Phentolamine